4//SEC Filing
Smith Brigitte 4
Accession 0001181431-13-007809
CIK 0001293310other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 7:37 PM ET
Size
20.4 KB
Accession
0001181431-13-007809
Insider Transaction Report
Form 4
Smith Brigitte
Director
Transactions
- Conversion
Common Stock
2013-02-05+825,613→ 850,613 total(indirect: See Footnote) - Conversion
Series B-2 Preferred Stock
2013-02-05−341,229→ 0 total(indirect: By GBS Bioventures II A/C)→ Common Stock (341,229 underlying) - Conversion
Series B-2 Preferred Stock
2013-02-05−146,240→ 0 total(indirect: By GBS Genesis)→ Common Stock (146,240 underlying) - Conversion
Series C Preferred Stock
2013-02-05−59,084→ 0 total(indirect: By GBS Bioventures II A/C)→ Common Stock (64,666.7 underlying) - Conversion
Series C Preferred Stock
2013-02-05−25,322→ 0 total(indirect: By GBS Genesis)→ Common Stock (27,714.6 underlying) - Conversion
Series D Preferred Stock
2013-02-05−170,617→ 0 total(indirect: By GBS Bioventures II A/C)→ Common Stock (194,140.4 underlying) - Conversion
Series D Preferred Stock
2013-02-05−45,368→ 0 total(indirect: By GBS Genesis)→ Common Stock (51,623 underlying)
Footnotes (10)
- [F1]Represents the sum of all converted shares described in Table II of this Form 4. The converted shares were first aggregated on a per entity basis and then rounded down to the next whole share. The shares are held as follows: 600,036 shares by GBS Bioventures II A/C ("Bioventures") and 225,577 shares by GBS Genesis Fund ("Genesis"). The Reporting Person is a managing director of GBS Venture Partners Pty Ltd which manages Bioventures and Genesis.
- [F10]Fractional shares were rounded as described in Footnote 1 of this Form 4.
- [F2]Each share of Series B-2 Preferred Stock automatically converted into one share of Common Stock in connection with the consummation of Issuer's initial public offering.
- [F3]Each share of Series C Preferred Stock automatically converted into approximately 1.09 shares of Common Stock, including applicable anti-dilution adjustments, in connection with the consummation of Issuer's initial public offering.
- [F4]Each share of Series D Preferred Stock automatically converted into approximately 1.14 shares of Common Stock, including applicable anti-dilution adjustments, in connection with the consummation of Issuer's initial public offering.
- [F5]The shares are held as follows: 625,036 shares by Bioventures and 225,577 shares by Genesis.
- [F6]Reflects 1-for-3.56147 reverse stock split which became effective on January 15, 2013.
- [F7]No expiration date.
- [F8]Represents shares held directly by Bioventures.
- [F9]Represents shares held directly by Genesis.
Documents
Issuer
KALOBIOS PHARMACEUTICALS INC
CIK 0001293310
Entity typeother
Related Parties
1- filerCIK 0001555775
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 7:37 PM ET
- Size
- 20.4 KB